---
title: Random Trial for Elderly Patients With NSCLC
nct_id: NCT00265694
overall_status: UNKNOWN
phase: PHASE3
sponsor: Inje University
study_type: INTERVENTIONAL
primary_condition: Non-Small Cell Lung Cancer
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00265694.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00265694"
ct_last_update_post_date: 2005-12-15
last_seen_at: "2026-05-12T06:22:11.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Random Trial for Elderly Patients With NSCLC

**Official Title:** A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer

**NCT ID:** [NCT00265694](https://clinicaltrials.gov/study/NCT00265694)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Lead Sponsor:** Inje University
- **Conditions:** Non-Small Cell Lung Cancer
- **CT.gov Last Update:** 2005-12-15

## Brief Summary

1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70 years of age or older demonstrated a definite improvement in overall survival rate and quality of life with chemotherapy.
2. The role of combination therapy containing the platinum compound, which is the standard therapy for the young patients is still vague.
3. Gemcitabine and carboplatin have favorable toxicity profile.

## Eligibility

- **Minimum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with pathologically confirmed, advanced(clinical stage IIIB or IV) NSCLC
* No previous chemotherapy history
* Age ≥ 65 years
* ECOG performance status ≤ 2
* Adequate marrow function (ANC ≥ 2,000/mm3, platelet ≥ 100,000/mm3), renal and liver function (total bilirubin \< 2.0 mg/dL, AST/ALT levels \< 3 × the upper limit of normal, serum creatinine \< 2.0 mg/dL)
* Patients with informed written consent

Exclusion Criteria:

* Patients with other major illness(active infection, severe heart disease, concomitant malignancy, etc)
```

## Interventions

- **vinorelbine, gemcitabine and carboplatin** (DRUG)

## Locations (1)

- Inje University Sanggyepaik Hospital, Seoul, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.inje university sanggyepaik hospital|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00265694.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00265694*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*